... The BTK inhibitors currently used are: Acalabrutinib (Calquence) Ibrutinib (Imbruvica) Pirtobrutinib (Jaypirca) Zanubrutinib (Brukinsa) BCL-2 InhibitorVenetoclax (Venclexta) is used to treat some cases of AML and CLL/SLL. ...
8 Leukemia Treatment Options You Should Know
... The BTK inhibitors currently used are: Acalabrutinib (Calquence) Ibrutinib (Imbruvica) Pirtobrutinib (Jaypirca) Zanubrutinib (Brukinsa) BCL-2 InhibitorVenetoclax (Venclexta) is used to treat some cases of AML and CLL/SLL. ...
... Targeted therapies used to treat CLL include: Bruton’s tyrosine kinase inhibitors, including Brukinsa (zanubrutinib), Calquence (acalabrutinib), and Imbruvica (ibrutinib) Phosphoinositide 3-kinase inhibitors, including Copiktra (duvelisib) and Zydelig (idelalisib) The B-cell lymphoma 2 inhibitor Venclexta (venetoclax) Monoclonal antibodies are another ...
Chronic Lymphocytic Leukemia Treatment Options
... Targeted therapies used to treat CLL include: Bruton’s tyrosine kinase inhibitors, including Brukinsa (zanubrutinib), Calquence (acalabrutinib), and Imbruvica (ibrutinib) Phosphoinositide 3-kinase inhibitors, including Copiktra (duvelisib) and Zydelig (idelalisib) The B-cell lymphoma 2 inhibitor Venclexta (venetoclax) Monoclonal antibodies are another ...